Literature DB >> 23148916

Reward and relief craving tendencies in patients with alcohol use disorders: results from the PREDICT study.

Angelika Glöckner-Rist1, Tagrid Lémenager2, Karl Mann3.   

Abstract

BACKGROUND: Previous research suggests that patients' tendencies toward either reward or relief craving are distinct continuous factorial dimensions of craving for alcohol. According to these tendencies patients with alcohol use disorders (AUD) might also be allocated into distinct subgroups. In personalized treatment, patients of such different subgroups might respond differently to various psychotherapeutic and pharmacological interventions aimed at relapse prevention.
OBJECTIVES: To establish that the items of the subscale Temptation to Drink of the Alcohol Abstinence Self-Efficacy Scale (AASE) capture two continuous dimensions of reward and relief craving, and that they allow the identification of respective discrete class factors and subgroups of patients with AUD.
METHODS: Nonlinear confirmatory factor analysis (CFA) and latent class factor analysis (LCFA) were performed with data from 426 detoxified patients with AUD. The validity of continuous relief and reward dimensions, discrete class factors, and subtypes with different craving tendencies was established by including past drinking in positive and negative settings, gender, trait anxiety and perceived stress as covariates in the finally accepted CFA and LCFA measurement models.
RESULTS: The AASE temptation items formed two continuous relief and reward craving factors. They also associated themselves to two binary class factors, which defined four craving subgroups. Two of them (21% and 29% of patients) were characterized by high levels of either reward or relief craving tendencies. A third subgroup (31%) rated both tendencies in an equal high measure, while a fourth (18%) reported almost no craving tendencies at all. Past drinking in negative and positive settings was significantly associated with relief or reward craving tendencies. Male patients reported reward drinking more frequently than female patients. Trait anxiety was positively related only to the relief craving tendency. Unexpectedly, patients' level of perceived stress was associated with both craving tendencies.
CONCLUSIONS: The AASE temptation items are suited to identify relief and reward craving dimensions and to assign patients to according subtypes. Thus, they can be used to screen for corresponding patient subgroups, possibly allowing allocation to interventions that are specifically tailored to patient's particular craving tendencies. Hence: A relatively simple psychometric measure could help in improving treatment outcomes through a personalized approach to intervention.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23148916     DOI: 10.1016/j.addbeh.2012.06.018

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  15 in total

1.  Reward, Relief and Habit Drinking: Initial Validation of a Brief Assessment Tool.

Authors:  Erica N Grodin; Spencer Bujarski; Alexandra Venegas; Wave-Ananda Baskerville; Steven J Nieto; J David Jentsch; Lara A Ray
Journal:  Alcohol Alcohol       Date:  2019-12-01       Impact factor: 2.826

2.  Functional alterations in the dorsal raphe nucleus following acute and chronic ethanol exposure.

Authors:  Emily G Lowery-Gionta; Catherine A Marcinkiewcz; Thomas L Kash
Journal:  Neuropsychopharmacology       Date:  2014-08-14       Impact factor: 7.853

3.  Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.

Authors:  Corey R Roos; Karl Mann; Katie Witkiewitz
Journal:  Addict Biol       Date:  2016-08-02       Impact factor: 4.280

Review 4.  The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?

Authors:  Matthew B Pomrenze; Tracy L Fetterly; Danny G Winder; Robert O Messing
Journal:  Alcohol Clin Exp Res       Date:  2017-10-25       Impact factor: 3.455

5.  Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.

Authors:  Karl Mann; Corey R Roos; Sabine Hoffmann; Helmut Nakovics; Tagrid Leménager; Andreas Heinz; Katie Witkiewitz
Journal:  Neuropsychopharmacology       Date:  2017-11-20       Impact factor: 7.853

6.  Psychiatric, Demographic, and Brain Morphological Predictors of Relapse After Treatment for an Alcohol Use Disorder.

Authors:  Timothy C Durazzo; Dieter J Meyerhoff
Journal:  Alcohol Clin Exp Res       Date:  2016-11-24       Impact factor: 3.455

7.  Examining temptation to drink from an existential perspective: Associations among temptation, purpose in life, and drinking outcomes.

Authors:  Corey R Roos; Megan Kirouac; Matthew R Pearson; Brandi C Fink; Katie Witkiewitz
Journal:  Psychol Addict Behav       Date:  2015-03-02

8.  Comparing factor, class, and mixture models of cannabis initiation and DSM cannabis use disorder criteria, including craving, in the Brisbane longitudinal twin study.

Authors:  Thomas S Kubarych; Kenneth S Kendler; Steven H Aggen; Ryne Estabrook; Alexis C Edwards; Shaunna L Clark; Nicholas G Martin; Ian B Hickie; Michael C Neale; Nathan A Gillespie
Journal:  Twin Res Hum Genet       Date:  2014-03-03       Impact factor: 1.587

9.  A Multimethod Examination of Sensitivity to Reward and Sensitivity to Punishment in Bipolar Disorder and Alcohol Dependence: Results from a 2 × 2 Factorial Design.

Authors:  William Mellick; James J Prisciandaro; Helena Brenner; Delisa Brown; Bryan K Tolliver
Journal:  Psychopathology       Date:  2021-02-17       Impact factor: 1.944

10.  Impact of a computerized intervention for high distress intolerance on cannabis use outcomes: A randomized controlled trial.

Authors:  Richard J Macatee; Brian J Albanese; Sarah A Okey; Kaveh Afshar; Meghan Carr; M Zachary Rosenthal; Norman B Schmidt; Jesse R Cougle
Journal:  J Subst Abuse Treat       Date:  2020-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.